883 related articles for article (PubMed ID: 30563566)
1. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
[TBL] [Abstract][Full Text] [Related]
2. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
3. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
4. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.
Fromm G; de Silva S; Giffin L; Xu X; Rose J; Schreiber TH
Cancer Immunol Res; 2016 Sep; 4(9):766-78. PubMed ID: 27364122
[TBL] [Abstract][Full Text] [Related]
5. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
6. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
7. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
[TBL] [Abstract][Full Text] [Related]
8. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J
Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045
[TBL] [Abstract][Full Text] [Related]
9. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection.
Li T; Ma R; Zhu J; Wang F; Huang L; Leng X
Chin Med J (Engl); 2014; 127(14):2686-92. PubMed ID: 25043090
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PD1:PD-L1 interaction by an E. coli-derived optimized PD1 variant.
Brand Shwartz M; Assor M; Dotan N; Ratzon E; Cohen E; Ruimi N; Bloch I; Gal M; Yadid I
Biochem Biophys Res Commun; 2018 Nov; 506(3):731-738. PubMed ID: 30384998
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
Roberts A; Bentley L; Tang T; Stewart F; Pallini C; Juvvanapudi J; Wallace GR; Cooper AJ; Scott A; Thickett D; Lugg ST; Bancroft H; Hemming B; Ferris C; Langman G; Robinson A; Chapman J; Naidu B; Pinkney T; Taylor GS; Brock K; Stamataki Z; Brady CA; Curnow SJ; Gordon J; Qureshi O; Barnes NM
Sci Rep; 2021 Feb; 11(1):4030. PubMed ID: 33597595
[TBL] [Abstract][Full Text] [Related]
13. Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response.
Ukyo N; Hori T; Yanagita S; Ishikawa T; Uchiyama T
Immunology; 2003 Jun; 109(2):226-31. PubMed ID: 12757617
[TBL] [Abstract][Full Text] [Related]
14. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.
Murphy KA; Lechner MG; Popescu FE; Bedi J; Decker SA; Hu P; Erickson JR; O'Sullivan MG; Swier L; Salazar AM; Olin MR; Epstein AL; Ohlfest JR
Clin Cancer Res; 2012 Sep; 18(17):4657-68. PubMed ID: 22781551
[TBL] [Abstract][Full Text] [Related]
15. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
[TBL] [Abstract][Full Text] [Related]
16. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
17. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.
Morris NP; Peters C; Montler R; Hu HM; Curti BD; Urba WJ; Weinberg AD
Mol Immunol; 2007 May; 44(12):3112-21. PubMed ID: 17374396
[TBL] [Abstract][Full Text] [Related]
19. OX40, OX40L and Autoimmunity: a Comprehensive Review.
Webb GJ; Hirschfield GM; Lane PJ
Clin Rev Allergy Immunol; 2016 Jun; 50(3):312-32. PubMed ID: 26215166
[TBL] [Abstract][Full Text] [Related]
20. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
[Next] [New Search]